Login / Signup

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model.

Chanho KongEun-Jeong YangJaewoo ShinJunwon ParkSi-Hyun KimSeong-Wook ParkWon Seok ChangChang-Han LeeHyunju KimHye-Sun KimJin Woo Chang
Published in: Translational neurodegeneration (2022)
In conclusion, the enhanced delivery of a low dose of Adu (3 mg/kg) via FUS decreases amyloid deposits and attenuates cognitive function deficits. FUS-mediated BBB opening increases adult hippocampal neurogenesis as well as drug delivery. We present an AD treatment strategy through the synergistic effect of the combined therapy of FUS and Adu.
Keyphrases
  • low dose
  • drug delivery
  • high dose
  • cancer therapy
  • traumatic brain injury
  • blood brain barrier
  • cerebral ischemia
  • type diabetes
  • metabolic syndrome
  • mesenchymal stem cells
  • adipose tissue
  • replacement therapy
  • cell therapy